<DOC>
	<DOCNO>NCT02535325</DOCNO>
	<brief_summary>This phase I trial study side effect best dose methoxyamine give together pemetrexed disodium , cisplatin , radiation therapy treat patient stage IIIA-IV non-small cell lung cancer . Drugs use chemotherapy , methoxyamine , pemetrexed disodium , cisplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Radiation therapy use high-energy x-ray kill tumor cell shrink tumor . Giving methoxyamine together pemetrexed disodium , cisplatin , radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Methoxyamine , Pemetrexed Disodium , Cisplatin , Radiation Therapy Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) methoxyamine ( TRC102 ) combination pemetrexed ( pemetrexed disodium ) -cisplatin thoracic radiotherapy . SECONDARY OBJECTIVES : I . To ( descriptively ) ass toxicity profile methoxyamine ( TRC102 ) combination pemetrexed-cisplatin thoracic radiotherapy . II . To ( descriptively ) ass short-term progression-free survival 6 month ( PFS6 ) patient treat protocol . III . To observe record anti-tumor activity . OUTLINE : This dose-escalation study methoxyamine . COURSES 1-2 : Patients receive pemetrexed disodium intravenously ( IV ) 10 minute methoxyamine orally ( PO ) day 1 ; cisplatin IV 0.5-24 hour day 3 . Patients also undergo 3-dimensional ( 3-D ) conformal radiation therapy ( RT ) intensity-modulated radiation therapy ( IMRT ) daily ( QD ) 5 day week ( 3 day week 1 4 day week 4 ) 30 fraction total . COURSES 3-4 : Beginning least 10 day RT completion , patient receive pemetrexed disodium IV 10 minute cisplatin IV 0.5-24 hour day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 week every 3 month 6 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Patients must pathologic diagnosis adenocarcinoma large cell carcinoma lung confirmation immunohistochemistry ( e.g. , transcription termination factor 1 [ TTF1 ] positivity ) ( histologic tissue diagnosis recommend , cytology acceptable ) ; stage IIIA/IIIB oligometastatic stage IV patient still consider appropriate candidate aggressive chemoradiotherapy primary tumor ; oligometastatic disease define = &lt; 5 metastatic site ( = &lt; 3 lesion per organ ) ; intracranial metastasis , patient asymptomatic disease stable steroid 1 3 symptomatic metastatic lesion treat stereotactic radiosurgery ( SRS ) Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Life expectancy great 12 month Ability swallow retain orallyadministered medication clinically significant gastrointestinal abnormality ( e.g. , malabsorption syndrome major resection stomach bowel ) Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 × institutional upper limit normal Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 × institutional upper limit normal Creatinine within normal institutional limit OR Creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Hemoglobin &gt; = 9 g/dL without transfusion within 7 day prior enrollment Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men woman treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion methoxyamine administration Ability understand willingness sign write informed consent document Patients prior chemotherapy investigational drug within 30 day registration prior radiotherapy study treatment volume ; prior surgery allow ; must least 6 week mitomycin nitrosoureas new therapy Patients receive investigational agent Patients history active malignancy require ongoing treatment , except basal cell carcinoma squamous cell carcinoma skin History allergic reaction attribute compound similar chemical biologic composition methoxyamine pemetrexed cisplatin Undetectable haptoglobin evidence glucose6phophate dehydrogenase ( G6PD ) deficiency , pyruvate kinase deficiency , hemoglobinopathy , hereditary spherocytosis , thalassemia disorder associate hemolysis Patients receive medication substance inhibitor inducer nonsteroidal antiinflammatory drug ( NSAIDS ) , probenecid , salisylates , sulfonamide ineligible ; concomitant drug sensitive cytochrome P450 ( CYP450 ) substrates strong moderate CYP450 inducer inhibitor avoid ; part enrollment/informed consent procedure , patient counsel risk interaction agent , new medication need prescribe patient consider new overthecounter medicine herbal product Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated methoxyamine Patients know human immunodeficiency positive ( HIV ) positive combination antiretroviral therapy ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>